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Temporal trends in initiation of 
VKA, rivaroxaban, apixaban and 
dabigatran for the treatment of 
venous thromboembolism - A 
Danish nationwide cohort study
Caroline Sindet-Pedersen1,2,3, Jannik Langtved Pallisgaard1,2, Laila Staerk1,2, Jeffrey S. 
Berger3, Morten Lamberts1,4, Christian Torp-Pedersen1,5, Gunnar H. Gislason1,2,6,7 & Jonas 
Bjerring Olesen1
Danish nationwide registries were used to investigate temporal trends in initiation of rivaroxaban or 
apixaban or dabigatran versus vitamin K antagonists (VKA) in patients with venous thromboembolism 
(VTE). Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were 
identified between February 2012 and September 2016. A total of 19,578 patients were included of 
which 10,844 (55.4%) were treated with VKA and 8,734 (44.6%) were treated with NOACs (rivaroxaban 
7,572, apixaban 1,066, and dabigatran 96). Temporal trends showed a decrease in the initiation of VKA 
(p-value for decreasing trend, p < 0001) and an increase in the initiation of rivaroxaban and apixaban 
(p-value for increasing trend, p < 0001). By September 2016, 12%, 70%, 16%, and 2% of patients 
with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran. Patients with previous VTE, 
chronic kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA 
compared with one of the NOACs. In conclusion the initiation of rivaroxaban and apixaban is increasing 
significantly over time in patients with VTE. Patients with previous VTE, chronic kidney disease, liver 
disease, cancer, and thrombophilia were more likely to be initiated on VKA compared with rivaroxaban 
or apixaban.
For decades, vitamin K antagonists (VKA) have been the foundation of treatment of venous thromboembolism 
(VTE)1, 2. While VKA is effective in treating VTE, the treatment has several drawbacks, which includes narrow 
therapeutic interval, need for frequent blood tests, bridging therapy, and interactions with food and drugs1, 3, 4. 
This has encouraged the development of non-VKA antagonist oral anticoagulants (NOACs)1, 2. Randomized con-
trolled trials have investigated the safety and efficacy of the individual NOACs compared with VKA, finding these 
agents non-inferior to VKA with regard to efficacy, and associated with either equal or lower risk of major bleed-
ing5–9. In Denmark, rivaroxaban was the first NOAC to be approved for the treatment of VTE (6th of February 
2012), followed by dabigatran (6th of June 2014) and apixaban (31st of July 2014). The American College of Chest 
Physicians treatment guidelines for VTE now recommend the initiation of a NOAC over VKA in patients without 
cancer, renal impairment, and liver disease10. Danish and European guidelines do not differentiate between the 
individual NOACs or VKA for the treatment of VTE11. Knowledge on the real-world initiation of NOACs for 
VTE is lacking and it is expected that the use of NOACs has increased since their approval and thus replacing the 
1Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, 2900, Hellerup, Denmark. 
2Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen N, Denmark. 3New York 
University School of Medicine, New York, New York, USA. 4Department of Cardiology, Copenhagen University 
Hospital Rigshospitalet, 2100, Copenhagen Ø, Denmark. 5Department of Health, Science and Technology, Aalborg 
University, and Department of Epidemiology/Biostatistics and Cardiology, Aalborg University Hospital, Aalborg, 
Denmark. 6The National Institute of Public Health, University of Southern Denmark, 1353, Odense, Denmark. 7The 
Danish Heart Foundation, 1127 Copenhagen K, Copenhagen, Denmark. Correspondence and requests for materials 
should be addressed to C.S. (email: carolinesindet@gmail.com)
Received: 8 February 2017
Accepted: 2 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 3347  | DOI:10.1038/s41598-017-03596-x
role of VKA. Little is known about which patients initiate rivaroxaban, apixaban or dabigatran versus VKA. The 
aims of this study were i) to examine temporal trends in initiation of the individual NOACs and VKA in VTE 
patients; ii) to assess potential differences in patient characteristics between those who initiate OAC treatment 
with one of the individual NOACs versus VKA.
Results
A total of 21,765 patients were eligible for inclusion (Fig. 1). After excluding patients, the study population com-
prised 19,578 patients of, which 10,844 (55.4%) were treated with VKA, 7,572 (38.7%) were treated with rivar-
oxaban, 1,066 (5.4%) were treated with apixaban, and 96 (0.5%) were treated with dabigatran (Table 1). In the 
study population a total of 11,772 (60.2%) patients had deep vein thrombosis (DVT) as inclusion event, and 7,806 
(39.8%) patients had pulmonary embolism (PE) as inclusion event. Patients with DVT accounted for 61.9%, 
59.9%, 44.2%, 52.1%, and 59.9% and in the VKA, rivaroxaban, apixaban, and dabigatran group respectively.
Temporal initiation. VKA was the preferred treatment at the beginning of the study period, with a stead-
ily decline in the initiation until September 2016 (p-value for decreasing trend < 0001) (Fig. 2). An increase 
in the initiation of rivaroxaban was observed in the same period (p-value for increasing trend < 0001) (Fig. 2, 
and Supplementary Figure 1). By September 2016, 70% of patients with VTE were initiated on rivaroxaban vs. 
12% initiated on VKA. From August 2014 to September 2016, the initiation of apixaban in patients with VTE 
increased from 1% to 16% (p-value for increasing trend < 0001). The use of dabigatran remained low during the 
whole study period, with 2% of patients with VTE initiated on dabigatran by September 2016 (Fig. 2). Similar 
observations were noted in patients with DVT or PE. By September 2016, 12%, 71%, 15% and 2% of patients 
diagnosed with DVT were initiated on VKA, rivaroxaban, apixaban and dabigatran respectively. Similarly 6%, 
69% 25% and 0% of patients diagnosed with PE, were initiated on VKA, rivaroxaban, apixaban and dabigatran, 
respectively.
Factors associated with initiation of a NOAC versus VKA. Table 2 shows factors associated with ini-
tiation of rivaroxaban, apixaban or dabigatran vs. VKA. Patients with previous VTE, chronic kidney disease, can-
cer, and thrombophilia were more likely to be initiated on VKA compared with either rivaroxaban or apixaban. 
However, because of the low number of patients in the dabigatran group, there were no significant differences in 
any factors associated with initiation of dabigatran vs. VKA. Patients with ischemic heart disease, liver disease, 
hypertension, previous stroke, and COPD were significantly more likely to be initiated on VKA compared with 
rivaroxaban. Patients older than 75, or patients with pulmonary embolism as index event, were significantly 
more likely to be initiated on apixaban compared with VKA. When dividing patient according to inclusion event 
(DVT or PE), similar factors were found to be associated with initiation of either one of the NOACs vs. VKA 
(Supplementary Tables 3 and 4). When the total NOAC group was compared with the VKA group, similar results 
were found in patients with VTE, DVT and PE (Supplementary Table 5).
Figure 1. Selection of study cohort. Flow chart of selection process for the study population in the period 
between February 2012 and September 2016.
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Discussion
This study investigated temporal trends in the initiation of oral anticoagulation therapy in patients with VTE. 
This study had two main findings: i) initiation of VKA declined whereas initiation of rivaroxaban and apixaban 
increased since their approval, while there were no temporal difference in the initiation of dabigatran. ii) Patients 
with chronic kidney disease, liver disease, thrombophilia, previous VTE, and cancer were more likely to be initi-
ated on VKA compared with rivaroxaban or apixaban.
The cumbersome treatment with VKA has urged the development of NOACs, and results from this study 
showed that especially the initiation of rivaroxaban is being extensively implemented into clinical practice. 
Similar to this study, Badreldin et al.12 found in a cohort of VTE patients that only 2% of patients initiated dab-
igatran compared with 53%, 40%, and 5% initiated on rivaroxaban, apixaban, and edoxaban, respectively12. A 
plausible explanation for the low initiation of dabigatran could be that the treatment needs to be accompanied 
by parenteral heparin for at least 5 days7. In the RECOVER (Dabigatran versus warfarin in the treatment of acute 
venous thromboembolism) I and II trials, parenteral heparin was used for a median length of 7 days post rand-
omization; hence evidence is lacking to support the use of dabigatran as mono-therapy without initial concomi-
tant treatment with heparin7, 9, 13. On the contrary, rivaroxaban and apixaban were studied as mono-therapy in the 
VKA (10,844)
Rivaroxaban 
(n = 7,572)
Apixaban 
(n = 1,066)
Dabigatran 
(96)
Patient characteristic
Median age (IQR+) 66 [53–76] 66 [52–76] 69 [55–79] 71 [59–80]
Males (%) 5,775 (53.3) 4,109 (54.3) 532 (49.9) 45 (46.9)
Index event (%)
PE 4,130 (38.1) 3,035 (40.1) 595 (55.8) 46 (47.9)
DVT 6,714 (61.9) 4,537 (59.9) 471 (44.2) 50 (52.1)
Comorbidities (%)
Previous venous 
thromboembolism 1,973 (18.2) 911 (12.0) 101 (9.5) 10 (10.4)
Previous bleeding 1,099 (10.1) 691 (9.1) 111 (10.4) 9 (9.4)
Stroke 759 (7.0) 420 (5.5) 88 (8.3) 8 (8.3)
Acute myocardial infarction 426 (3.9) 205 (2.7) 51 (4.8) <3
Ischemic heart disease 1,249 (11.5) 676 (8.9) 148 (13.9) 6 (6.2)
Peripheral vascular disease 307 (2.8) 148 (2.0) 23 (2.2) 3 (3.1)
Vascular disease 685 (6.3) 342 (4.5) 69 (6.5) 5 (5.2)
Chronic heart failure 509 (4.7) 332 (4.4) 49 (4.6) 4 (4.2)
Chronic kidney disease 550 (5.1) 188 (2.5) 38 (3.6) 0 (0.0)
Liver disease 224 (2.1) 112 (1.5) 21 (2.0) <3
Hypertension 2,796 (25.8) 1,723 (22.8) 286 (26.8) 16 (16.7)
Diabetes mellitus 839 (7.7) 542 (7.2) 88 (8.3) 7 (7.3)
Cancer 1,499 (13.8) 844 (11.1) 134 (12.6) 15 (15.6)
COPD 1077 (9.9) 618 (8.2) 123 (11.5) 16 (16.7)
Thrombophilia § 211 (1.9) 71 (0.9) 4 (0.4) 0 (0.0)
Alloplastic surgery 205 (1.9) 169 (2.2) 23 (2.2) <3
Concomitant medication (%)
ADP-receptor blockers 518 (4.8) 366 (4.8) 84 (7.9) 10 (10.4)
Aspirin 1,814 (16.7) 1,016 (13.4) 167 (15.7) 10 (10.4)
Diuretics 2,436 (22.5) 1,509 (19.9) 250 (23.5) 18 (18.8)
Beta-blockers 1,649 (15.2) 969 (12.8) 169 (15.9) 8 (8.3)
Calcium channel blockers 1,701 (15.7) 1,023 (13.5) 177 (16.6) 10 (10.4)
Renin-angiotensin system 
blockers 3,055 (28.2) 1,939 (25.6) 310 (29.1) 21 (21.9)
Loop diuretics 1,417 (13.1) 785 (10.4) 140 (13.1) 16 (16.7)
Ulcer medication 2,555 (23.6) 1,625 (21.5) 284 (26.6) 24 (25.0)
Lipid modifying agents 2,188 (20.2) 1,420 (18.8) 232 (21.8) 14 (14.6)
Hormone replacement 
therapy 601 (5.5) 448 (5.9) 68 (6.4) 4 (4.2)
Oral contraceptives 547 (5.0) 367 (4.8) 41 (3.8) <3
Non steroidal anti- 
inflammatory drugs 2,041 (18.8) 1,437 (19.0) 209 (19.6) 17 (17.7)
Table 1. Table of patient characteristics in apixaban, dabigatran, VKA and rivaroxaban groups. 
+IQR = Interquartile Range. §Thrombophilia (factor v Leiden, prothrombin mutation, protein C, S, and 
antithrombin deficiency, antiphospholid syndrome and cardiolipin syndrome). PE: Pulmonary embolism. DVT: 
Deep venous thromboembolism. COPD: Chronic obstructive pulmonary disease.
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EINSTEIN (Oral rivaroxaban for symptomatic venous thromboembolism and oral rivaroxaban for symptomatic 
pulmonary embolism) trial and in the AMPLIFY (Oral apixaban for the treatment of acute venous thromboem-
bolism) trial5, 6, 14. Hence, the advantage of using dabigatran over either rivaroxaban or apixaban may be perceived 
as less apparent.
Results from this study showed that the odds of initiating treatment with NOACs in patients with cancer, 
renal impairment, and liver disease were significantly lower compared with VKA. The trials that established the 
safety and effectiveness of NOACs were not designed to investigate outcomes in patients with cancer, chronic 
kidney disease, or liver disease as most of these patients were excluded5–7, 9, 13. In our study, patients were classified 
as having had previous cancer that had occurred up to ten years prior to their diagnosis of VTE, thus there was 
no differentiation between active or previous cancer. In general, patients with active cancer are given parenteral 
anticoagulation therapy, sometimes as bridging to VKA10, 11. These patients have a poor prognosis, complicated by 
a high risk of recurrent VTE and high risk of bleeding15–17. The lower odds for initiating patients with cancer on 
Figure 2. Temporal trends in initiation of anticoagulation therapy. Graph of temporal trend over initiation 
of oral anticoagulation therapy in patients with venous thromboembolism (VTE). Percentage of patients with 
VTE, pulmonary embolism (PE) or deep venous thromboembolism (DVT) initiating VKA, rivaroxaban, 
apixaban or dabigatran per month between February 2012 and September 2016. Rivaroxaban: p- value for 
increasing trend < 0.001, apixaban: p-value for increasing trend < 0.001, dabigatran: pValue for increasing 
trend < 0.991. VKA: p-value for decreasing trend < 0.001.
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a NOAC is likely explained by the perception from physicians that NOACs are not recommended in this patient 
group. Concerns have been raised about a possible increased risk of bleeding in patients with chronic kidney 
disease and liver failure, because of the pharmacokinetic profile of NOACs, which are contraindicated in patients 
with severe kidney disease (eGFR < 15 ml/min)5–7, 9, 13. The results from this study are in accordance with The 
American College of Chest Physician new guidelines from 2016, recommending initiation of a NOAC over VKA 
in patients without cancer, renal impairment, and liver disease10. The most recent guidelines from the European 
Society of Cardiology from 2014 do not differentiate between the choice of NOACs or VKA11, 18.
Interestingly, patients with indication for prolonged treatment, such as patients with previous VTE and 
thrombophilia were more likely to be initiated on a VKA compared with one of the NOACs10, 11. Even though 
the safety and efficacy of extended treatment with NOACs have been examined in randomized controlled trials, 
only dabigatran was directly compared with VKA in the REMEDY trial (Extended use of dabigatran, warfarin, 
or placebo in venous thromboembolism)19, while rivaroxaban and apixaban were compared with placebo in the 
EINSTEIN-EXT and AMPLIFY-EXT (Apixaban for extended treatment of venous thromboembolism)5, 20. As a 
result of this, Danish guidelines suggest that VKA should be used for extended treatment instead of NOACs. This 
also emphasizes the need for comparative safety and effectiveness studies to establish the risk-benefit profile of 
rivaroxaban and apixaban compared with VKA for extended treatment21.
The primary strength of this study is inherent in the use of the Danish nationwide registries, which have been 
associated with high internal validity, as the registration of diagnoses is considered reliable22–24. Several diagnoses 
have been validated through the registries, and relevant to this study the diagnosis of VTE has been associated 
with a positive predictive value between 75% and 90%25, 26. Another benefit is that the registries allow for the 
inclusion of all Danish residents and provide complete information regardless of socioeconomic status, geogra-
phy, or participation in a health care insurance program, which increases the generalizability of results. Denmark 
has a reimbursement system for drugs, and therefore it is uncertain if the results from this study are representative 
for other countries. Despite the reimbursement system, NOACs still have a higher acquisition cost for the patient 
than VKA in Denmark, which is approximately three times higher for NOACs than for VKA. Unfortunately, we 
variables
Odds ratios
Rivaroxaban vs. VKA Apixaban vs. VKA
Dabigatran vs. 
VKA
Sex
Female Ref Ref Ref
Male 1.05 (0.98–1.12) 1.04 (0.90–1.21) 0.88 (0.58–1.33)
Age groups
<65 Ref Ref Ref
65–75 1.01 (0.92–1.10) 0.99 (0.81–1.20) 1.42 (0.83–2.39)
>75 1.00 (0.92–1.09) 1.31 (1.08–1.58)* 1.61 (0.96–1.36)
Index event
Deep venous 
thrombosis Ref Ref Ref
Pulmonary embolism 1.05 (0.98–1.12) 1.68 (1.44–1.95)* 1.20 (0.79–1.82)
Comorbidities
Previous VTE 0.78 (0.71–0.86)* 0.73 (0.57–0.93)* 0.68 (0.33–1.27)
Previous bleeding 1.01 (0.90–1.13) 0.92 (0.72–1.18) 0.82 (0.37–1.58)
Alloplastic surgery 1.22 (0.97–1.54) 1.03 (0.60–1.70) 0.97 (0.16–3.23)
Chronic kidney disease 0.42 (0.34–0.50)* 0.47 (0.32–0.69)* NA
Liver disease 0.73 (0.57–0.95)* 0.93 (0.54–1.55) NA
Heart failure 1.26 (1.06–1.50) 0.80 (0.55–1.16) 1.03 (0.30–2.74)
Ischemic heart disease 0.87 (0.75–0.99)* 1.21 (0.91–1.59) 0.45 (0.13–1.14)
Vascular disease 0.89 (0.70–1.13) 0.72 (0.40–1.22) 1.44 (0.34–4.05)
Hypertension 0.89 (0.82–0.97)* 0.93 (0.77–1.11) 0.48 (0.26–0.83)*
Acute myocardial 
infarction 0.85 (0.62–1.17) 1.49 (0.77–2.29) 0.76 (0.08–5.97)
Cancer 0.74 (0.67–0.82)* 0.76 (0.60–0.94)* 0.92 (0.50–1.60)
Diabetes mellitus 1.00 (0.88–1.14) 0.95 (0.71–1.24) 0.94 (0.39–1.97)
Stroke 0.86 (0.75–0.99)* 1.19 (0.90–1.56) 1.30 (0.57–2.61)
COPD 0.88 (0.78–0.99)* 1.08 (0.84–1.37) 1.80 (0.99–3.10)
Thrombophilia 0.58 (0.42–0.78)* 0.27 (0.08–0.69)* 1.75 (0.96–3.02)
Year (with 1 year 
increments) 2.21 (2.15–2.27)* 4.49 (4.14–4.89)* 2.76 (2.30–3.35)*
Table 2. Factors associated with initiation of rivaroxaban, apixaban, or dabigatran, vs. VKA in patients with 
VTE. Odds ratio below 1 indicates in favor of VKA and above 1 in favor of rivaroxaban, apixaban or dabigatran. 
*Indicates significance.
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do not have information on socioeconomic or sociodemographic status in the utilized databases, which poten-
tially are important factors for the initiation of a NOAC vs. VKA. Furthermore, there is a lack of important 
clinical variables that are not readily available through the registries, which includes: International normalized 
ratio, body mass index, smoking status, hepatic status, kidney function, and blood pressure. Since edoxaban was 
approved in Denmark subsequent to the study period, it was not possible to include this drug in the study.
In conclusion the initiation of NOACs, driven by rivaroxaban and apixaban, is increasing in patients with 
VTE, whereas the initiation of VKA is decreasing. By September 2016 12%, 70%, 16%, and 2% were initiated on 
VKA, rivaroxaban, apixaban, and dabigatran. Patients with previous VTE, chronic kidney disease, liver disease, 
cancer, and thrombophilia were significantly more likely to be initiated on VKAs compared with rivaroxaban or 
apixaban.
Methods
Data sources. In this Danish nationwide study data from three different registers were included: The Danish 
National Prescription Registry, the Danish National Patient Register, and The Danish Civil Registration System. 
All Danish residents are provided with a unique civil registration number, which enables individual-level linkage 
between the registries22, 27. The Danish Civil Registration System provides information on: vital status, gender, 
date of birth, and date of emigration and immigration27. The Danish National Patient Register provides infor-
mation on all hospital admissions (in-patient and out-patient). Patients are registered with a primary diagnosis, 
being the primary reason for admission, and if necessary one or more secondary diagnoses. All hospital diagnoses 
in the register are classified according to the International Classification of Diseases, 10th revision (ICD-10). All 
surgical procedures are registered according to the Nordic Classification of Surgical Procedures (NCPS)23. The 
Danish Registry of Medicinal Product Statistics provides information on all prescribed drugs redeemed at all 
Danish pharmacies, and includes information on strength, dosage, and date of redemption. All drugs are classi-
fied according to the Anatomical Therapeutic Chemical (ATC) classification system22.
Study population. All patients diagnosed with VTE (in-patients and out-patients, primary and secondary 
diagnoses) in the period 6th of February 2012 to 30th of September 2016 were identified. Patients were included 
if they had redeemed a prescription of rivaroxaban, dabigatran, apixaban, or VKA 7 days prior or 7 days after 
the date of discharge with a VTE or date of diagnosis from an out-patient clinic, as has been performed previ-
ously28. Patients treated with VKA or rivaroxaban were included from the 6th of February 2012, which was the 
date of approval of rivaroxaban. Patients treated with dabigatran or apixaban were included if they had redeemed 
a prescription after the 6th of June 2014 or 31st of July 2014, respectively, which were the dates of approval for 
these two drugs. Patients under 15 and over 100 years of age, and patients with atrial fibrillation were excluded. 
Furthermore, patients with mechanical heart valves were excluded.
Comorbidities and concomitant medication. Comorbidities of interest were identified from the Danish 
National Patient Registry using ICD-10 diagnosis codes (Supplementary Tables 1 and 2). Comorbidities were 
registered within 10 years of a diagnosis with VTE. Baseline pharmacotherapy was identified through the Danish 
Registry of Medicinal Product Statistics using ATC-codes (Supplementary Tables 1 and 2). Redeemed prescrip-
tions were identified within 180 days prior to the VTE diagnosis.
Statistical analyses. Patient characteristics were presented as frequencies with percentages and as medi-
ans with interquartile ranges (IQR). Differences in baseline characteristics of included patients were investi-
gated using the Chi-square test for discrete variables and Kruskal-Wallis rank sum test for continuous variables. 
Initiation of treatment with VKA rivaroxaban, apixaban, or dabigatran was plotted each month as the percentage 
of patients treated divided by the total number of patients initiating treatment. The temporal trends in initiation 
of rivaroxaban, apixaban, dabigatran and VKAs were investigated using the Cochran–Armitage test for trend. 
Multivariable logistic regression modeling, adjusted for calendar year, was used to investigate factors associ-
ated with the initiation of treatment with rivaroxaban, apixaban, and dabigatran vs. VKA. All statistical analyses 
were performed at a 0.05 significance level. Data management and statistical analysis were performed using SAS 
(Statistical Analytical System, version 9.4, SAS Institute, Gary, NC.) and R29.
Ethics. Retrospective registry-based studies do not require approval from the Research Ethics Committee 
System. The Danish Data Protection Agency had approved use of data for this study (ref. no: 2007-58-0015/GEH-
2014-012 I-Suite no: 02720).
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